These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 28914846)

  • 1. [Analysis of the efficiency of antimicrobial treatment for community-acquired pneumonia in clinical practice].
    Zhukova OV; Ruina OV; Kononova SV; Konyshkina TM
    Ter Arkh; 2017; 89(8):17-21. PubMed ID: 28914846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.
    Rosón B; Carratalà J; Tubau F; Dorca J; Liñares J; Pallares R; Manresa F; Gudiol F
    Microb Drug Resist; 2001; 7(1):85-96. PubMed ID: 11310807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patients.
    Izadi M; Dadsetan B; Najafi Z; Jafari S; Mazaheri E; Dadras O; Heidari H; SeyedAlinaghi S; Voltarelli F
    Recent Pat Antiinfect Drug Discov; 2018; 13(3):228-239. PubMed ID: 30360748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study.
    Frei CR; Jaso TC; Mortensen EM; Restrepo MI; Raut MK; Oramasionwu CU; Ruiz AD; Makos BR; Ruiz JL; Attridge RT; Mody SH; Fisher A; Schein JR
    Curr Med Res Opin; 2009 Apr; 25(4):859-68. PubMed ID: 19231913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poor outcomes of empiric ceftriaxone ± azithromycin for community-acquired pneumonia caused by methicillin-susceptible Staphylococcus aureus.
    So W; Crandon JL; Nicolau DP
    Intern Emerg Med; 2016 Jun; 11(4):545-51. PubMed ID: 26531307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of antimicrobial resistance on health outcomes in the out-patient treatment of adult community-acquired pneumonia: a probability model.
    Singer ME; Harding I; Jacobs MR; Jaffe DH
    J Antimicrob Chemother; 2003 May; 51(5):1269-82. PubMed ID: 12697646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
    Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of initial antibiotic therapy for community-acquired pneumonia in U.S. hospitals, 2000 to 2009.
    Berger A; Edelsberg J; Oster G; Huang X; Weber DJ
    Am J Med Sci; 2014 May; 347(5):347-56. PubMed ID: 24029796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia.
    Clark LC; Davis CW
    Am J Health Syst Pharm; 2000 Nov; 57 Suppl 3():S10-3. PubMed ID: 11098314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Italian experience of sequential intravenous and oral azithromycin plus intravenous ampicillin/sulbactam in hospitalized patients with community-acquired pneumonia.
    Todisco T; Dal Farra F; Ciliberti G; Pirina P; Guelfi R; Serra G; Paris R; Mancuso I; Cepparulo M
    J Chemother; 2008 Apr; 20(2):225-32. PubMed ID: 18467250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic utilization and cost analysis in hospitalized patients with community-acquired pneumonia.
    Stein GE; Mantz SL
    Hosp Pharm; 1995 Feb; 30(2):132-4, 137. PubMed ID: 10140526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).
    Noreddin AM; Marras TK; Sanders K; Chan CK; Hoban DJ; Zhanel GG
    Int J Antimicrob Agents; 2004 Nov; 24(5):479-84. PubMed ID: 15519481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sputum bacteriology and antibiotic sensitivity patterns of community-acquired pneumonia in hospitalized adult patients in Nigeria: a 5-year multicentre retrospective study.
    Iroezindu MO; Chima EI; Isiguzo GC; Mbata GC; Onyedum CC; Onyedibe KI; Okoli LE
    Scand J Infect Dis; 2014 Dec; 46(12):875-87. PubMed ID: 25288384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The comparative development of elevated resistance to macrolides in community-acquired pneumonia caused by Streptococcus pneumoniae.
    Yayan J
    Drug Des Devel Ther; 2014; 8():1733-43. PubMed ID: 25336917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
    Jones RN; Sader HS; Stilwell MG; Fritsche TR
    Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial susceptibility of Streptococcus pneumoniae isolates from vaccinated and non-vaccinated patients with a clinically confirmed diagnosis of community-acquired pneumonia in Belgium.
    Lismond A; Carbonnelle S; Verhaegen J; Schatt P; De Bel A; Jordens P; Jacobs F; Dediste A; Verschuren F; Huang TD; Tulkens PM; Glupczynski Y; Van Bambeke F
    Int J Antimicrob Agents; 2012 Mar; 39(3):208-16. PubMed ID: 22245497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics of community-acquired pneumonia due to Moraxella catarrhalis in adults: a retrospective single-centre study.
    Hirai J; Kinjo T; Koga T; Haranaga S; Motonaga E; Fujita J
    BMC Infect Dis; 2020 Nov; 20(1):821. PubMed ID: 33172398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial treatment of lower respiratory tract infections in the hospital setting.
    Grossman RF; Rotschafer JC; Tan JS
    Am J Med; 2005 Jul; 118 Suppl 7A():29S-38S. PubMed ID: 15993675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI).
    Kuzman I; Bezlepko A; Kondova Topuzovska I; Rókusz L; Iudina L; Marschall HP; Petri T
    BMC Pulm Med; 2014 Jun; 14():105. PubMed ID: 24975809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic options for pneumococcal pneumonia in Turkey.
    Oncu S; Erdem H; Pahsa A
    Clin Ther; 2005 Jun; 27(6):674-83. PubMed ID: 16117975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.